Verigen launches cartilage repair service
This article was originally published in Clinica
Verigen has launched its autologous chondrocyte implantation (ACI) service in Denmark, Sweden and Norway. ACI was developed at Sahlgrenska Hospital in Gothenburg, Sweden, and involves taking healthy cartilage from the good knee, culturing and multiplying the chondrocytes in a laboratory and returning the cells to the bad knee to repair the cartilage.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.